Treatments for Infantile Hemangioma: A Systematic Review and Network Meta-analysis

Overview

Journal EClinicalMedicine

Specialty General Medicine

Date 2020 Oct 22

PMID 33089121

Citations 7

Authors

Qiang Fei

Yu Lin

Xian Chen

Affiliations

Soon will be listed here.

Abstract

Background: Infantile hemangioma (IH) is common in children, which may bring about cosmetically disfiguring, functional impairment, and exhibiting complications. There had been various therapies and we aimed to assess the efficacy and adverse effects of different therapies through network meta-analysis.

Methods: We searched PubMed, Embase, Cochrane Library and Web of Science (from database inception to April 11, 2020) for studies assessing the efficacy, success rate and adverse effects. Direct pairwise comparison and a network meta-analysis under random effects were performed. We also assessed the ranking probability.

Findings: A total of 30 randomized clinical trials with more than 20 different therapeutic regimens were identified. Treatment combined propranolol orally with laser could improve the curative effect than monotherapy. Laser with topical β blockers showed more efficiency than others whether in children under 6 months or not. The long-pulsed dye laser might be the best laser therapy. A higher dose and a longer treatment duration of propranolol orally achieved a higher success rate and increased side effects. Plus pulse dye laser with propranolol had the lowest incidence of adverse reactions, such as ulcer, color sink and color reduction.

Interpretation: A combination of β blockers and laser might be the first-line treatment of IHs and a longer pulsed dye laser is preferred.

Funding: No funding was received.

Citing Articles

IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway.

Liu Z, Ma T, Li J, Ren W, Zhang Z Oncol Res. 2024; 32(9):1453-1465.

PMID: 39220137 PMC: 11361910. DOI: 10.32604/or.2024.048315.

Historical and contemporary management of infantile hemangiomas: a single-center experience.

Zou Y, Wu Z, Jin P, Fu R, Cheng J, Bai H Front Pharmacol. 2024; 15:1280948.

PMID: 38370473 PMC: 10869534. DOI: 10.3389/fphar.2024.1280948.

IADVL SIG Pediatric Dermatology (Academy) Recommendations on Hemangioma of Infancy (HOI).

Katakam B, Chiramel M, Gulati R, Gupta M, Munisamy M, Ranugha P Indian Dermatol Online J. 2023; 14(2):172-186.

PMID: 37089858 PMC: 10115319. DOI: 10.4103/idoj.idoj_52_22.

Association of robot-assisted techniques with the accuracy rates of pedicle screw placement: A network pooling analysis.

Wei F, Gao Q, Heng W, Zhu K, Yang F, Du R EClinicalMedicine. 2022; 48:101421.

PMID: 35706496 PMC: 9193845. DOI: 10.1016/j.eclinm.2022.101421.

Treatment patterns and outcomes in children with infantile hemangiomas: A retrospective observational analysis.

Cai Y, Ge Y, Ung C, Li F, Wang J, Xia C SAGE Open Med. 2021; 9:20503121211056844.

PMID: 34938569 PMC: 8685728. DOI: 10.1177/20503121211056844.

References

Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G . A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015; 372(8):735-46. DOI: 10.1056/NEJMoa1404710. View

Ji Y, Li K, Xiao X, Zheng S, Xu T, Chen S . Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg. 2012; 47(12):2216-23. DOI: 10.1016/j.jpedsurg.2012.09.008. View

Zhu H, Liu Q, Deng X, Guan Y . Efficacy of low-dose Sr-Y therapy combined with topical application of 0.5% timolol maleate solution for the treatment of superficial infantile hemangiomas. Exp Ther Med. 2015; 10(3):1013-1018. PMC: 4533184. DOI: 10.3892/etm.2015.2609. View

Zaher H, Rasheed H, Esmat S, Hegazy R, Gawdat H, Hegazy R . Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. Eur J Dermatol. 2013; 23(5):646-52. DOI: 10.1684/ejd.2013.2146. View

Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J, Taieb A . Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008; 358(24):2649-51. DOI: 10.1056/NEJMc0708819. View

Caldwell D, Ades A, Higgins J . Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331(7521):897-900. PMC: 1255806. DOI: 10.1136/bmj.331.7521.897. View

Krowchuk D, Frieden I, Mancini A, Darrow D, Blei F, Greene A . Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2018; 143(1). DOI: 10.1542/peds.2018-3475. View

Malik M, Menon P, Rao K, Samujh R . Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg. 2013; 48(12):2453-9. DOI: 10.1016/j.jpedsurg.2013.08.020. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

10.

Gong H, Xu D, Li Y, Cheng C, Li G, Wang X . Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. Br J Oral Maxillofac Surg. 2015; 53(9):836-40. DOI: 10.1016/j.bjoms.2015.09.005. View

11.

Lou H, Xu G, Huo R . Curative effect and safety of propranolol combined with prednisone in the treatment of infantile hemangiomas. Exp Ther Med. 2018; 15(6):4677-4682. PMC: 5952068. DOI: 10.3892/etm.2018.6035. View

12.

Laken P . Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use. Adv Neonatal Care. 2016; 16(2):135-42. DOI: 10.1097/ANC.0000000000000254. View

13.

Li G, Xu D, Tong S, Xue L, Sun N, Wang X . Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. J Craniofac Surg. 2015; 27(1):56-60. DOI: 10.1097/SCS.0000000000002221. View

14.

Satterfield K, Chambers C . Current treatment and management of infantile hemangiomas. Surv Ophthalmol. 2019; 64(5):608-618. DOI: 10.1016/j.survophthal.2019.02.005. View

15.

Tan M, Duan B, Zhou C, Gong H . [The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2012; 28(3):164-8. View

16.

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

17.

Salanti G . Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2015; 3(2):80-97. DOI: 10.1002/jrsm.1037. View

18.

Chen Z, Wang Q, Zhu Y, Zhou L, Xu T, He Z . Progress in the treatment of infantile hemangioma. Ann Transl Med. 2020; 7(22):692. PMC: 6944559. DOI: 10.21037/atm.2019.10.47. View

19.

Chinnadurai S, Sathe N, Surawicz T . Laser treatment of infantile hemangioma: A systematic review. Lasers Surg Med. 2015; 48(3):221-33. DOI: 10.1002/lsm.22455. View

20.

Zhong S, Tao Y, Zhou J, Liu Y, Yao L, Li S . Infantile Hemangioma: Clinical Characteristics and Efficacy of Treatment with the Long-Pulsed 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser in 794 Chinese Patients. Pediatr Dermatol. 2015; 32(4):495-500. DOI: 10.1111/pde.12593. View